S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

Key facts

Sponsor

SWOG Cancer Research Network

Principal Investigator

Peter McSweeney, MD

Rocky Mountain Cancer Centers - Denver Midtown

Intervention

therapeutic allogeneic lymphocytes(biological)

Enrollment

5 enrolled

Eligibility

55-69 years · All sexes

Timeline

2003 – 2006

Study locations (30)

• Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
• Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States
• Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
• Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Veterans Affairs Medical Center - Little Rock, Little Rock, Arkansas, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Scripps Cancer Center at Scripps Clinic, La Jolla, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
• Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
• Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California, United States
• Sutter Cancer Center, Sacramento, California, United States
• University of California Davis Cancer Center, Sacramento, California, United States
• Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
• General Robert Huyser Cancer Center at David Grant Medical Center, Travis Air Force Base, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06710418
  Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
  University of Washington
• RECRUITINGPHASE3NCT07007312
  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
  Kura Oncology, Inc.
• RECRUITINGPHASE1, PHASE2NCT06928662
  Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
  Fred Hutchinson Cancer Center
• RECRUITINGPHASE1NCT07106749
  CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE1NCT06448013
  A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT06245746
  UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• RECRUITINGNCT06452732
  Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
  Peking University People's Hospital
• RECRUITINGNCT06458257
  The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
  Ruijin Hospital

See all trials for Acute myeloid leukemia with 11q23 abnormalities →